Estimating the Loss in Expectation of Life and Relative Survival Rate among Hemodialysis Patients in Iran

Seyedghasemi, Navisa Sadat; Bahrampour, Abbas; Etminan, Abbas; Haghdoost, Ali-Akbar; Baneshi, Mohammad Reza

doi:10.34172/jrhs.2020.21

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with end-stage renal disease (ESRD) have a poor life expectancy as well as high perioperative mortality and morbidity. [1][2][3] Two major causes of ESRD, diabetes mellitus and hypertension, may also exacerbate aortic disease. 4 A great number of studies show that the risks of cardiovascular surgery in hemodialysis patients are especially high and may outweigh the benefits.…”

Section: Introductionmentioning

confidence: 99%

Endovascular treatment of type B aortic dissection in patients with end-stage renal disease

Zhou

Ding

et al. 2022

Vascular

View full text Add to dashboard Cite

Objectives This study aimed to evaluate the postoperative and intermediate outcomes of thoracic endovascular aortic repair (TEVAR) in patients with end-stage renal disease (ESRD). Methods We retrospectively reviewed patients with type B aortic dissection (TBAD) undergoing TEVAR at our single center from January 2010 to December 2020. Patients with pre-existing ESRD were enrolled as the study group. One hundred consecutive patients from September 2013 to March 2015 without ESRD were included as the control group. The primary and secondary outcomes were adverse events and survival, respectively. Kaplan–Meier curves of survival and freedom from adverse events were calculated and analyzed using the log-rank univariate test. Multivariable analysis was used to isolate the effects of ESRD. Results A total of 39 patients with ESRD and TBAD underwent TEVAR during the study period. The median follow-up time of patients with and without ESRD was 45 and 46 months, respectively. There was significant difference between the survival at 4 years of patients with and without ESRD (72.8% vs 94.9%; p = 0.011). Meanwhile, the incidence of adverse events was significantly higher in patients with ESRD ( p = 0.026). Multivariable logistic regression analysis showed that ESRD (OR, 2.46; p = 0.049) and peripheral artery disease (OR, 4.11; p = 0.002) were the predictors of adverse events. Conclusions The rates of adverse events and survival expectancy were poor in patients with ESRD and TBAD.

show abstract

Section: Introductionmentioning

confidence: 99%

Endovascular treatment of type B aortic dissection in patients with end-stage renal disease

Zhou

Ding

et al. 2022

Vascular

View full text Add to dashboard Cite

show abstract

Relative survival in patients with cancer and kidney failure

Oliveras,

Rosales,

De La Mata

et al. 2024

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background and hypothesis The population with kidney failure is at increased risk of cancer and associated mortality. Relative survival can provide insight into the excess mortality, directly or indirectly, attributed to cancer in the population with kidney failure. Methods We estimated relative survival for people all ages receiving dialysis (n = 4089) and kidney transplant recipients (n = 3253) with de novo cancer, and for the general population with cancer in Australia and New Zealand (n = 3 043 166) over the years 1980–2019. The entire general population was the reference group for background mortality, adjusted for sex, age, calendar year and country. We used Poisson regression to quantify excess mortality ratios. Results Five-year relative survival for all-site cancer was markedly lower than the general population for people receiving dialysis (0.25, 95%CI:0.23–0.26) and kidney transplant recipients (0.55, 95%CI:0.53–0.57). In dialysis, excess mortality was more than double (2.16, 95%CI:2.08–2.25) that of the general population with cancer and for kidney transplant recipients 1.34 higher (95%CI:1.27–2.41). There was no difference in excess mortality from lung cancer between people with kidney failure and the general population with cancer. Comparatively, there was a significant survival deficit for people with kidney failure, compared to the general population with cancer, for melanoma, breast cancer and prostate cancers. Conclusion Decreased cancer survival in kidney failure may reflect differences in multi-morbidity burden, reduced access to treatment, or greater harm from or reduced efficacy of treatments. Our findings support research aimed at investigating these hypotheses.

show abstract

Estimating the Loss in Expectation of Life and Relative Survival Rate among Hemodialysis Patients in Iran

Cited by 2 publications

References 33 publications

Endovascular treatment of type B aortic dissection in patients with end-stage renal disease

Endovascular treatment of type B aortic dissection in patients with end-stage renal disease

Relative survival in patients with cancer and kidney failure

Contact Info

Product

Resources

About